3 ASX 200 healthcare shares to buy while they're on sale

The ASX 200 Health Care Index is the worst-performing sector for 2026 so far.

A severe sector-wide downturn has put ASX healthcare 200 shares under significant pressure this year driven by macroeconomic pressures, a weaker US dollar, rising inflation, higher cost-of-living, and regulatory uncertainty.

The S&P/ASX 200 Health Care Index (ASX: XHJ) is the worst performing sector by far in 2026 and has significantly unperformed the broader index. The decrease has pushed many major ASX healthcare companies to multi-year lows.

At the time of writing, the ASX 200 Health Care Index is down around 34% for the year to date and 47% lower than 12 months ago.

For context, the wider S&P/ASX 200 Index (ASX: XJO) is largely flat for the year to date and 3% higher than this time last year.

Sector wide declines might look concerning, but I think it presents a great opportunity for investors to buy into ASX 200 healthcare shares for cheap.

Here are three stocks that I'd buy today, while they're on sale.

A group of people in a corporate setting do a collective high five.

Image source: Getty Images

ResMed Inc (ASX: RMD)

ResMed shares have fallen to a two-year low this week and are down 28% for the year so far. The global leader in sleep health was swept up in the general sector-wide ASX healthcare sell-off. Its latest third-quarter earnings update also came in softer than expected, which didn't help lessen declining sentiment. But I think the ASX 200 healthcare share is now oversold and below fair value. Sleep disorders require long-term management, and as a global leader, ResMed has a powerful position in a large (and growing) market. According to Market Index data, brokers have a strong buy consensus on ResMed shares and tip a 67% upside to an average $43.38 target price, at the time of writing.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

Fisher & Paykel shares have rebounded around 14% since hitting a two-year low in mid-May, but the shares have still got some more room to run before they return to 2025-levels. At the time of writing, the shares are still down around 6% for the year to date and they're 11% lower than 12 months ago. Investors have been buying this medical device company's shares following the release of its strong FY26 result last month, which showed investors that the business is sound. The ASX 200 healthcare company reported a 14% increase in total operating revenue and a 24% increase in NPAT. Brokers rate the shares as a strong buy and tip a potential 21% upside to an average $36.90 target price, at the time of writing.

Pro Medicus Ltd (ASX: PME)

Pro Medicus shares have rebounded around 21% since the health imaging technology company announced a new contract win. In late May, the ASX 200 healthcare company confirmed it has signed a five-year, A$28 million contract renewal with Allegheny Health Network (AHN). The increase has helped recoup some, but not all losses shed by the company over the past year. Pro Medics shares are still around 28% lower for the year to date and 43% below their trading price this time last year. The company's US subsidiary also won two $40 million five-year contract renewals back in early March. It looks like we'll see plenty more out of the company over the next 12 months, too. The majority of brokers rate the ASX 200 healthcare shares as a strong buy and tip an 18% upside to an average $188.51 target price, at the time of writing.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope typing on her computer.
Healthcare Shares

$128 million contract win: Are Pro Medicus shares a strong buy?

I remain a fan of this healthcare technology company, and today's announcement gives me another reason to be optimistic.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »